Network Pharmacology Research of Huanglian in Treatment of Polycystic Ovary Syndrome with Hyperandrogenism

OBJECTIVE To explore the material basis and mechanism of Huanglian in the treatment of polycystic ovary syndrome with hyperandrogenism （PCOS-HA） based on network pharmacology. METHODS With the help of TCMSP to collect the compounds and effective targets of Huanglian， the compound-target network was constructed by Cytoscape software， the disease targets of the data screening of GeneCards， OMIM and CTD were collected， and the effective targets of the drug were analyzed by Venny to determine the intersection targets. The target protein interaction network was constructed with String database， and the gene function GO enrichment analysis and KEGG pathway enrichment analysis were carried out by DAVID database. RESULTS 11 active compounds， 111 drug targets， 370 disease targets and 37 intersecting targets were obtained. The PPI network involved 30 protein nodes， with key targets including FOS， JUN， IL-6， MAPK1， NCOA2， CCL2， ESR1. GO functional enrichment analysis was mainly related to positive regulation of transcription， response to drug， transcription initiation from RNA polymerase Ⅱ promoter， aging and so on. 46 KEGG Access were mainly involved TNF signaling pathway and FoxO signaling pathway. CONCLUSION The network pharmacology confirms the multi-component， multi-target and multi-pathway action characteristics of huanglian which predicts the possible mechanism of it in the treatment of PCOS-HA， and provides theoretical basis for further study of the active ingredients and mechanism.